CNBC
Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline
EconomyDaily Composite
Merck is trying to bulk up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.
C
Source
CNBC
Read full article at CNBC
Opens original article in a new tab
Advertisement